We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...